someone sent me  this:

http://www.earthclinic.com/CURES/parkinsons.html#MB

There  was a study about the effect on M Blue on Alzheimer. I don't suppose 
any 
lab  would fund the research on it because there is no profit in it, the 
stuff 
is  dirt cheap

maryse
 
Maryse, this just in:


   
Methylene  Blue: Drug Safety Communication - Serious CNS Reactions Possible 
When Given to  Patients Taking Certain Psychiatric Medications
AUDIENCE:  Emergency Medicine, Critical Care Medicine, Psychiatry 
ISSUE:  FDA has received reports of serious central nervous system (CNS) 
reactions when  the drug methylene blue is given to patients taking 
psychiatric medications that  work through the serotonin system of the brain 
(serotonergic psychiatric  medications). A list of the serotonergic psychiatric 
medications that can  interact with methylene blue can be found in the Drug 
Safety Communication.  Safety information about this potential drug interaction 
and important drug  usage recommendations for emergency and non-emergency 
situations are being added  to the drug labels for serotonergic psychiatric 
medications. 
BACKGROUND:  Methylene blue is used to treat methemoglobinemia, vasoplegic 
syndrome,  ifosfamide-induced encephalopathy, and cyanide poisoning. It is 
also used as a  dye in therapeutic and diagnostic applications. Methylene 
blue is a potent,  reversible monoamine oxidase inhibitor (MAOI). Although the 
exact mechanism of  this drug interaction is unknown, methylene blue 
inhibits the action of  monoamine oxidase A — an enzyme responsible for breaking 
down serotonin in the  brain. It is believed that when methylene blue is given 
to patients taking  serotonergic psychiatric medications, high levels of 
serotonin can build up in  the brain, causing toxicity. This is referred to as 
Serotonin Syndrome — signs  and symptoms include mental changes (confusion, 
hyperactivity, memory problems),  muscle twitching, excessive sweating, 
shivering or shaking, diarrhea, trouble  with coordination and/or fever. 
A  separate Drug Safety Communication (DSC) is being released today for 
Zyvox  (linezolid) due to similar potential drug interactions with serotonergic 
 psychiatric medications and includes drug usage recommendations. 
RECOMMENDATION:  Methylene blue should generally not be given to patients 
taking serotonergic  drugs. However, there are some conditions that may be 
life-threatening or  require urgent treatment with methylene blue such as when 
it is used in the  emergency treatment of methemoglobinemia, 
ifosfamide-induced encephalopathy, or  cyanide poisoning. 
Patients  should not stop taking their serotonergic psychiatric medicine 
without first  talking to a healthcare professional. Read the Drug Safety 
Communication below  for other specific recommendations for Healthcare 
Professionals and for  Patients.

Healthcare  professionals and patients are encouraged to report adverse 
events or side  effects related to the use of these products to the FDA's 
MedWatch Safety  Information and Adverse Event Reporting Program: 
    *   Complete and  submit the report Online: 
_www.fda.gov/MedWatch/report.htm_ (http://www.fda.gov/MedWatch/report.htm)   
    *   _Download  form_ 
(http://www.fda.gov/Safety/MedWatch/HowToReport/DownloadForms/default.htm)  or call 1-800-332-1088 to request a reporting 
form, then complete and  return to the address on the pre-addressed form, or 
submit by fax to  1-800-FDA-0178 
Read  the MedWatch safety alert, including a link to the FDA Drug Safety  
Communication, at: 
_http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMe
dicalProducts/ucm265476.htm_ 
(http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm265476.htm)  
Tell us how we  are doing:

_http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg=
=&sid=link&cpp[date]=07_26_2011_1440&cpp[type]=S_ 
(http://survey.foreseeresults.com/survey/display?cid=d509U9xg0gZVxkMRcoMsQg==&sid=link&cpp[date]=07_26
_2011_1440&cpp[type]=S)  

  
____________________________________
  
 (http://www.fda.gov/)  
Subscriber  Services: 
_Manage Preferences_ 
(https://public.govdelivery.com/accounts/USFDA/subscriber/edit?preferences=true#tab1)   |  _Unsubscribe_ 
(https://public.govdelivery.com/accounts/USFDA/subscriber/edit?preferences=true#tab1)   |  _Help  
with this service_ (mailto:[log in to unmask])      Stay Connected:    
(http://www.facebook.com/FDA)   
(http://www.fda.gov/NewsEvents/InteractiveMedia/default.htm#micro)   (http://www.youtube.com/user/USFoodandDrugAdmin)   
(http://www.fda.gov/AboutFDA/ContactFDA/StayInformed/GetEmailUpdates/default.htm
)   (http://www.flickr.com/photos/fdaphotos/)   
(http://fdatransparencyblog.fda.gov/)  
  
____________________________________
     This email was sent to [log in to unmask] using GovDelivery,  on 
behalf of: U.S. Food & Drug Administration (FDA) · 10903 New  Hampshire Ave · 
Silver Spring, MD 20993 · 800-439-1420  
(http://www.govdelivery.com/portals/powered-by)

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn